Abstract
Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Anti-Infective Agents
Title:Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis
Volume: 10 Issue: 2
Author(s): Azam J. Samdani, Samreen, M. Iqbal Choudhary and Atta-ur-Rahman
Affiliation:
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Abstract: Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Export Options
About this article
Cite this article as:
J. Samdani Azam, Samreen , Iqbal Choudhary M. and Atta-ur-Rahman , Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020111
DOI https://dx.doi.org/10.2174/2211362611208020111 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Ascorbic Acid in Postoperative Intensive Care Patients - Biochemical Aspects and Clinical Experience
Current Medicinal Chemistry Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
Current Medicinal Chemistry Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Current Alzheimer Research Therapeutic Targets in Inflammatory Disease
Current Medicinal Chemistry Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Role of Toll-Like Receptors in Immune Responses to Chlamydial Infections
Current Pharmaceutical Design Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine The Therapeutic Potential of Quercetin in Parkinson’s Disease: Insights into its Molecular and Cellular Regulation
Current Drug Targets Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Possible Pathways of Hepatotoxicity Caused by Chemical Agents
Current Drug Metabolism Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) Emerging Mucus Regulating Drugs in Inflammatory and Allergic Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Non-Selective Inhibition of Cyclooxygenase Enzymes by Aminoacetylenic Isoindoline 1,3-Diones
Inflammation & Allergy - Drug Targets (Discontinued) ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Current Alzheimer Research